Elevated Cerebrospinal Fluid Substance P-like Immunoreactivity in Patients with Painful Osteoarthritis, but not in Patients with Rhizopatic Pain from a Herniated Lumbar Disc

References

• Euler US v, Gaddum J H. An unindentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931; 72: 74–87
   Google Scholar
• Harmar A, Schofield J G, Keen P. Substance P biosynthesis in dorsal root ganglia: An immunochemical study of [35S]methionine and [3H]-proline incorporation in vitro. Neuroscience 1981; 6: 1917–22
   PubMed Web of Science ®Google Scholar
• Pernow Substance B. P. Pharmacol Rev 1983; 35: 85–141
   PubMed Web of Science ®Google Scholar
• Saito T. Immunohistochemical study on the effect of high tibial osteotomy on the distribution pattern of neuropeptides in the synovium of the osteoarthritic knee. Nippon Seikeigeka Gakkai Zasshi 1992; 66: 884–97
   PubMedGoogle Scholar
• Ashton I K, Ashton B A, Gibson S J, Polak J M, Jaffray D C, Eisenstein S M. Morphological basis for back pain: the demonstration of nerve fibers and neuropeptides in the lumbar facet joint capsule but not in ligamentum flavum. J Orthop Res 1992; 10: 72–8
   PubMed Web of Science ®Google Scholar
• Ashton I K, Roberts S, Jaffray D C, Polak J M, Eisenstein S M. Neuropeptides in the human intervertebral disc. J Orthop Res 1994; 12: 186–92
   PubMed Web of Science ®Google Scholar
• Holmlund A, Ekblom A, Hansson P, Lind J, Lundeberg T, Theodorsson E. Concentrations of neuropeptides substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint. A correlation with symptoms, signs and artroscopic findings. Int J Oral Maxillofac Surg 1991; 20: 228–31
   PubMed Web of Science ®Google Scholar
• Almay B GL, Johansson F, Von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain 1988; 33: 3–9
   PubMed Web of Science ®Google Scholar
• Toresson G, Brodin E, Wahlstrom A, Bertilsson L. Detection of N-terminally extended substance P but not of substance P in human cerebrospinal fluid - quantitation with HPLC -RIA. J Neurochem 1988; 50: 1701–7
   PubMed Web of Science ®Google Scholar
• Clark J W, Senanayake P D, Solomon G D, Gallagher C. Substance P: correlation of CSF and plasma levels. Headache 1994; 34: 261–4
   PubMed Web of Science ®Google Scholar
• Ahmed M, Srinivasan G R, Bjurholm A, Theodorsson E, Kreicbergs A. Extraction and quantitation of neuropeptides in bone by radio-immunoassay. A study in the rat 1994; 179–88, Regul Pept 51
   Google Scholar
• Calvino B, Courand J Y, Besson J M. Prevaccination with diluted Freund adjuvant prevents the development of chronic pain and transient release of cerebrospinal fluid substance P in adjuvant arthritis in rats. Pain 1994; 58: 211–7
   PubMed Web of Science ®Google Scholar
• Ahmed M, Bjurholm A, Kreicbergs A, Schultzberg M, Theodorsson E. Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis. A combined immunohistochemical and radio-immunoassay analysis. Arthritis Rheum 1995; 38: 699–709
   PubMed Web of Science ®Google Scholar
• Vsroy H, Helle R, Førre Ø, Kåss E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynad's phenomenon in patients with fibromyalgia: new features for dignosis. Pain 1988; 32: 21–6
   PubMed Web of Science ®Google Scholar
• Russell I J, Orr M D, Littman B, Vipraio G A, Alboukrek D, Michalek J E. Elevated Cerebrospinal fluid levels of substance P in the fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593–601
   PubMed Web of Science ®Google Scholar
• Nyberg F. Substance P synthesis by enzymatic fragment condensation using product-directed antibodies as molecular traps. J Mol Recognit 1988; 1: 59–62
   PubMedGoogle Scholar
• Liu Z, Welin M, Bragee B, Thörnwall M, Nyberg F. Elevated substance P level in cerebrospinal fluid from patients with fibromyalgia is contrasted by a decrease in Met-enkephalin-Arg-Phe. Analgesia 1995; 1: 543–7
   Google Scholar
• Tomlinson D R, Robinson J P, Compton A M, Keen P. Essential fatty acid treatment - effects on nerve conduction polyol pathway and axonal transport in streptozotocin diabetic rats. Diabetologia 1989; 32: 655–9
   PubMed Web of Science ®Google Scholar
• Nyberg F, Moberg U, Pernow C, Eriksson R B. HPLC and diode array detection for identification of peptides containing aromatic amino acids in studies of endorphine degrading activity in the human CSF. J Chromatogr A 1986; 359: 541–51
   PubMed Web of Science ®Google Scholar
• Persson S, Jónsdóttir I, Thorén P, Post C, Nyberg F, Hoffman P. Cerebrospinal fluid dynorphin-converting enzyme activity is increased by voluntary exercise in the spontaneously hypertensive rat. Life Sci 1993; 53: 643–52
   PubMed Web of Science ®Google Scholar
• Nyberg F, Lyrenäs L, Danielsson Å. Fingerprinting of molecular components in individual human cerebrospinal samples with a new micropurification system. J Chromatogr A 1991; 548: 311–8
   Web of Science ®Google Scholar
• Arnalich F, De Miguel E, Perez-Ayala C, Martinez M, Vazquez J J, Gijon-Banos J. Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett 1994; 170: 251–4
   PubMed Web of Science ®Google Scholar
• Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon-Banos J, Arnalich F. Calcitonin-gene-related peptide II substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. BrJ Rheumatol 1993; 32: 31–5
   PubMedGoogle Scholar
• Sameshima K. Substance P-like immuno-reactivity in cerebrospinal fluid in lumbar disc herniation (in Japanese). Nippon Seikeigeka Gakkai Zasshi 1995; 69: 191–7
   PubMedGoogle Scholar
• Kawakami M, Tamaki T. Morphologic and quantitative changes in neurotransmitters in the lumbar spinal cord after acute or chronic mechanical compression of the cauda eqina. Spine 1992; 17(3S)S13–S17
   PubMedGoogle Scholar